Ultragenyx recebe IRL sobre a nova submissão da BLA para UX111

Trecho da fonte

EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update 2025 total revenue of $673 million, Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif. – February 12, 2025 – Ultrag

SEC 8-K

Mais sobre este ativo

Relevante

5 de mai. de 2026

20:06

RAREUltragenyx

Ultragenyx: FDA aceita BLA UX111, define data PDUFA para 19 set 2026

Pedido aceitoSEC 8-KAbrir registro

Relevante

3 de fev. de 2026

13:15

RAREUltragenyx

Ultragenyx resubmete BLA do UX111; PDUFA esperado para o 3T 2026

Pedido submetidoSEC 8-KAbrir registro